MedTrace Logo

Epidemiological and Scientific Evaluation of EGFR Mutation Status in Patients With Newly Diagnosed Locally Advanced or m

NCT00997230 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4243

Last updated 2013-10-28

No results posted yet for this study

Summary

The primary objective of the study is to collect epidemiological data on EGFR mutation status (M+, M-) in a population of predominantly Caucasian ethnicity and to correlate EGFR mutation status with clinico-pathological characteristics (e.g. smoking status, sex, histology, etc). In particular, the study will aim to determine the frequency of EGFR M+ lung cancers in patients with clinico-pathological characteristics that are not commonly associated with EGFR mutation positivity (i.e., smokers, men, and non-adenocarcinoma).

Conditions

  • Newly Diagnosed Locally Advanced or Metastatic Non-small Cell Lung Cancer

Sponsors & Collaborators

Principal Investigators

  • Prof. Dr. H. Brasch · AstraZeneca Germany

  • PD Dr. med. Wolfgang Schutte · 06120 Halle-Dolau, Germany

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2012-10-31
Completion
2012-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00997230 on ClinicalTrials.gov